UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii165

2018

Volltextzugriff (PDF)

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii156-viii157

2018

Volltextzugriff (PDF)

468PRegorafenib for metastatic colorectal carcinoma: A registry-based analysis

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

491PImpact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Neoadjuvant chemotherapy AC-D in breast cancer patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e11009-e11009

2010

Volltextzugriff (PDF)

Changes in HER2 status after neoadjuvant treatment of breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11110-e11110

2011

Volltextzugriff (PDF)

Pregnancy-associated breast cancer (PABC): Czech Young Breast Cancer Study Group Project 35

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.265-265

2011

Volltextzugriff (PDF)

Pharmacogenomic prediction of breast cancer treatment outcome with adjuvant tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11501-e11501

2009

Volltextzugriff (PDF)

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1077-1077

2010

Volltextzugriff (PDF)

Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.818-818

2005

Volltextzugriff (PDF)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

The Lancet (British edition), 2013-03, Vol.381 (9869), p.805-816

2013

Volltextzugriff (PDF)

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

The Lancet (British edition), 2011-11, Vol.378 (9804), p.1707-1716

2011

Volltextzugriff (PDF)

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3638-3651

2020

Volltextzugriff (PDF)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

British journal of cancer, 2014-11, Vol.111 (11), p.2051-2057

2014

Volltextzugriff (PDF)

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Annals of oncology, 2023-10, Vol.34, p.S1295-S1295

2023

Volltextzugriff (PDF)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Cancer management and research, 2020-01, Vol.12, p.5365-5372

2020

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

Cancer management and research, 2019-01, Vol.11, p.359-368

2019

Volltextzugriff (PDF)

168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry

Annals of oncology, 2016-12, Vol.27, p.ix53-ix53

2016

Volltextzugriff (PDF)

Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

Annals of oncology, 2017-09, Vol.28, p.v175-v175

2017

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

340 Breast Cancer Patients Resistant to Endocrine Therapy Show Decreased Number of Cytotoxic Supressor Cells and Enhanced Production of Neoangiogenetic and Immunosupressive Factors

European journal of cancer (1990), 2012-03, Vol.48, p.S142-S142

2012

Volltextzugriff (PDF)

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

Cancers, 2023-01, Vol.15 (2), p.418

2023

Volltextzugriff (PDF)

Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy

Neoplasma, 2014, Vol.61 (1), p.90-98

2014

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(63)

Sprache

Englisch
(52)
Tschechisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

468PRegorafenib for metastatic colorectal carcinoma: A registry-based analysis

491PImpact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Neoadjuvant chemotherapy AC-D in breast cancer patients

Changes in HER2 status after neoadjuvant treatment of breast cancer

Pregnancy-associated breast cancer (PABC): Czech Young Breast Cancer Study Group Project 35

Pharmacogenomic prediction of breast cancer treatment outcome with adjuvant tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months

Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry

168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry

Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

340 Breast Cancer Patients Resistant to Endocrine Therapy Show Decreased Number of Cytotoxic Supressor Cells and Enhanced Production of Neoangiogenetic and Immunosupressive Factors

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy

Suchergebnisse filtern